SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending after its cancer drug ANKTIVA received conditional marketing authorization from the European Commission, expanding its approval to 33 countries and fueling strong community anticipation of a significant short squeeze. The community is actively discussing the drug's potential as a broad cancer treatment and speculating on further global partnerships and upcoming regulatory catalysts.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is currently trending ahead of its highly anticipated earnings report, driving a significant debate among the community. Investors are sharply divided between those expecting continued growth driven by its defensive consumer staples position and e-commerce initiatives, and those expressing strong concerns about its elevated valuation relative to historical norms and industry peers.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is trending ahead of its earnings report, with community discussion polarized between strong bullish sentiment fueled by recent insider buying and analyst upgrades, and bearish concerns over its high valuation, intense competition, consumer spending pressures, and challenges with driver compensation and regulatory oversight.

WorldFinancial

WorldFinancial (WLFI) is a focal point of discussion as its Mar-a-Lago forum, featuring prominent financial leaders, drives anticipation for potential institutional adoption and further integration of its USD1 stablecoin. This bullish sentiment is countered by ongoing U.S. House investigations into the Trump-linked crypto project's foreign investments and alleged conflicts of interest, fueling a polarized community debate.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Cape Canaveral, FL.

Starfighters Space Inc

Starfighters Space Inc. (FJET) is trending due to significant upward momentum and widespread community speculation about an impending short squeeze, fueled by its extremely low float and high short interest. This is set against the broader backdrop of the highly anticipated Space X IPO, which is prompting intense debate among traders regarding FJET's potential for explosive gains within the space sector, despite some skepticism over its business fundamentals.

Tidal Trust II - YieldMax MSTR Short Option Income Strategy ETF

YieldMax MSTR Short Option Income Strategy ETF

YieldMax MSTR Short Option Income Strategy ETF (WNTR) is trending after experiencing a trading halt due to increased volatility, sparking active community discussion around its weekly dividend payouts and its role as an effective inverse hedge against MSTY amidst MicroStrategy's recent performance.

SolarEdge Technologies, Inc. engages in the development of energy technology, which provides inverter solutions. The firm operates through the following segments: Solar and All Other. The Solar segment includes the design, development, manufacturing, and sales of an inverter solution designed to maximize power generation. The All Other segment includes the design, development, manufacturing and sales of UPS products, energy storage products, e-Mobility products, and automated machines. Its products and services include photovoltaic inverters, power optimizers, photovoltaic monitoring, software tools, and electric vehicle chargers. The company was founded by Guy Sella, Lior Handelsman, Yoav Galin, Meir Adest, and Amir Fishelov on August 7, 2006 and is headquartered in Herzliya, Israel.

Solaredge Technologies Inc

SolarEdge Technologies is trending intensely after its Q4 earnings report, which, despite a net loss, exceeded revenue and EPS estimates and highlighted a strategic pivot towards AI data center power infrastructure. This news triggered a significant pre-market rally before a sharp reversal, sparking a contentious debate among traders over the company's long-term financial health versus the immediate impact of AI-driven sentiment and short-covering dynamics.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Wingstop is actively discussed following recent earnings, with investors cheering robust global expansion and strong EPS beats, leading to numerous analyst upgrades. However, a segment of the community remains concerned about the stock's high valuation and declining domestic same-store sales amid broader challenges in the fast-casual sector.

QuickLogic Corp. operates as a semiconductor company, which designs, markets, and supports primarily Customer Specific Standard Products and secondarily, Field Programmable Gate Arrays, sensor software algorithms, software drivers, associated design software and programming hardware. It develops and markets low power customizable semiconductor and software algorithm solutions that enable customers to differentiate their products by adding new features, extending battery life, becoming more contextually aware and improving the visual experience with their mobile, consumer and enterprise products. The company was founded by John M. Birkner, Andrew K. Chan, and Hua-Thye Chua in 1988 and is headquartered in San Jose, CA.

Quicklogic Corp

Substantial defense contract awards for its Strategic Radiation Hardened program, alongside strategic advancements in chiplet technology including the PACE ecosystem and collaboration with Intel's 18A process, are propelling QuickLogic's market conversation. While the community is optimistic about these catalysts driving significant revenue growth in 2026 and potential Russell 2000 re-entry, some caution remains due to past execution delays and notable short interest.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack In The Box is trending amidst a formal activist investor stake and its "Jack on Track" turnaround plan, which includes the Del Taco sale, while the community intensely debates the company's substantial debt and recent operational struggles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

D. Boral Capital Reiterates Buy Rating for Estrella Immunopharma (NASDAQ:ESLA)

D. Boral Capital reissued a "buy" rating and issued a $8.00 price target on shares of Estrella Immunopharma in a research report on Monday...

Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT & CIBMTR

Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...

Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT & CIBMTR

Estrella Immunopharma, Inc. (Nasdaq: ESLA) (Estrella or the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...

Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (the Company), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune...

Short Interest in Estrella Immunopharma, Inc. (NASDAQ:ESLA) Grows By 28.5%

Estrella Immunopharma, Inc. (NASDAQ:ESLA - Get Free Report) saw a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 709,318 shares, an...

Estrella Immunopharma (NASDAQ:ESLA) Trading 1.3% Higher - Here's Why

Estrella Immunopharma (NASDAQ:ESLA) Trading 1.3% Higher - What's Next...

Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (Estrella or the Company), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancer and...

Estrella Immunopharma (NASDAQ:ESLA) Raised to "Hold" at Wall Street Zen

Wall Street Zen upgraded Estrella Immunopharma to a "hold" rating in a research note on Saturday...

Candel Therapeutics Inc. (13% jump in followers)Candel Therapeutics Inc. shares gained momentum as Wall Street analysts&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-jumps-on-canaccord-buy-rating/ch5uUlPRwp">highlighted</a> the potential of its lead cancer drug candidate, CAN-2409. Canaccord expects continued clinical success in prostate, pancreatic, and non-small cell lung cancer, noting a significant increase in median overall survival in testing so far. Citi’s modeling suggests CAN-2409 could extend survival in localized prostate cancer by as much as eight to nine years over radiotherapy alone.&nbsp;The stock is up over 35% year-to-date.Acelyrin Inc. (12% jump in followers)Acelyrin confirmed that Concentra Biosciences, controlled by Tang Capital Partners, submitted an unsolicited offer to acquire all outstanding shares of Acelyrin for $3.00 per share in cash, plus a contingent value right tied to future licensing or asset sales.Earlier in the month, Acelyrin announced a merger agreement with Alumis in an all-stock transaction expected to close in the second quarter of 2025, pending shareholder approval.&nbsp;Acelyrin stock is down over 18% year-to-date.Solid Biosciences Inc. (11% jump in followers)Solid Biosciences shares surged after early-stage data from its gene therapy candidate SGT-003 for Duchenne muscular dystrophy&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sldb-stock-soars-on-dmd-trial-data/ch5rNeJRvt">showed</a> promising results.&nbsp;Following the data release, Chardan raised its price target on the stock and increased the therapy’s probability of success to 48%, citing strong early efficacy signals and manageable safety risks.Solid Biosciences stock is up 43% year-to-date.Estrella Immunopharma Inc. (11% jump in followers)Estrella Immunopharma received a bullish initiation from D. Boral Capital, which started coverage with a ‘Buy’ rating and a $16 price target. The firm sees Estrella as a potential major player in immuno-oncology, with its EB103 therapy using ARTEMIS T-cell engineering technology to target solid tumors.&nbsp;The company also completed the first dose cohort in its Phase I/II trial, receiving approval from the Data and Safety Monitoring Board to proceed to the second dose level.&nbsp;Estrella stock is up over 22% year-to-date.Aditxt Inc. (10% jump in followers)Aditxt announced that its subsidiary, Pearsanta, has engaged Dominari Securities as the lead underwriter for its planned initial public offering. The IPO aims to support Pearsanta’s U.S. and international commercial launch of its Mitomic Technology platform for early cancer detection.&nbsp;Pearsanta is developing a non-invasive blood test to detect cancer at earlier stages by leveraging mitochondrial DNA deletions as biomarkers. IPO proceeds will fund the U.S. launch of its Laboratory Developed Tests (LDTs) and drive global commercialization through distribution partnerships and regulatory approvals.&nbsp;Aditxt stock is down over 53% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Woman examining laboratory samples - stock photo | Image source: Getty Images

Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

Equity

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.


Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company was founded on March 30, 2022 and is headquartered in Emeryville, CA.

Estrella Immunopharma Inc

Fundamental

Technical

A mix of both

Some investors focus on company fundamentals like earnings, growth, and valuation. Others rely on price action, trends, and momentum. Many use a combination of both to guide their decisions. What do you use?

What type of analysis drives your investment decisions?

Current Price	$1.23
Prev Close	$1.28
Open	$1.23
Dividend Yield	0.00%
50-Day Moving Average	$1.38
Beta	0.68
Avg. Volume	88,316.70
PE Ratio	-3.46

52-Week High	$3.15
52-Week Low	$0.7301
Market Capitalization	$53.8M
EPS (Annual)	-$0.2425
Price to Book	-4.91
Revenue Per Employee	N/A

ESLA
Estrella Biopharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ESLA News

ESLAEstrella Biopharma Inc